1,721,146 research outputs found

    Electrophysiologic properties of intravenous Tenormine in man

    No full text
    The acute electrophysiologic effects of intravenous Tenormine (0.1 mg/kg body weight), a new cardioselective beta-adrenoreceptor blocking drug, were studied in 18 subjects with estimated normal impulse formation and conduction. The most significant (P less than 0.01) effects were sinus cycle lengthening, depression of intranodal conduction and prolongation of AV node refractory periods. Sinus node recovery time, sinoatrial conduction time and atrial refractory periods were only slightly prolonged (P less than 0.05). Intraatrial conduction and infra-His conduction were unchanged. These properties are compared with those of the most commonly employed beta-blocking agents. The clinical implications are discussed

    Endothelin-receptor antagonists in the management of pulmonary arterial hypertension: where do we stand?

    No full text
    Michele Correale,1 Armando Ferraretti,2 Ilenia Monaco,3 Davide Grazioli,1 Matteo Di Biase,4 Natale Daniele Brunetti3 1Department of Cardiology, Ospedali Riuniti University Hospital, Foggia, 2Cardiology Unit, “Caduti in guerra” Hospital, Canosa di Puglia, BT, 3Department of Cardiology, University of Foggia, 4Santa Maria Hospital, GVM Care and Research, Bari, Italy Abstract: Pulmonary arterial hypertension, a disease largely neglected until a few decades ago, is presently the object of intense studies by several research teams. Despite considerable progress, pulmonary arterial hypertension remains a major clinical problem, because it is not always easy to diagnose, treat, and prevent. The disease was considered incurable until the late 1990s, when Epoprostenol was introduced as the first tool against this illness. More recently, therapy for pulmonary arterial hypertension gained momentum after publication of the SERAPHIN and AMBITION trials, which also highlighted the importance of upfront therapy. This review also focuses on recent substudies from these trials and progress in drugs targeting the endothelin pathway. Future perspectives with regard to endothelin-receptor antagonists are also discussed. Keywords: endothelin-receptor antagonists, pulmonary arterial hypertension, Bosentan, ambrisentan, sitaxentan, macitenta

    Do environmental and occupational exposure to pyrethroids and organophosphates affect human semen parameters? Results of a systematic review and meta-analysis

    No full text
    Our purpose was to review and analyse the impact of pyrethroids and organophosphates exposure on human semen parameters. A comprehensive literature search was performed through MEDLINE via PubMed, Scopus and Webscience. Only cohort studies examining semen parameters in workers or general populations exposed to pyrethroids or organophosphates were included. Ejaculate volume, sperm count, concentration, motility, viability, normal morphology and seminal pH alterations were pooled using the Cochran–Mantel–Haenszel Method with the random effect model and expressed as weighted mean difference, risk ratios, 95% confidence intervals and p-values. Seven cross-sectional studies regarding pyrethroids were included. Four of them were eligible for meta-analysis. The only parameter affected by pyrethroid exposure was normal sperm morphology (WMD-7,61%, 95%CI –11,92 to −3,30;p = 0,0,005). Nine studies were selected to evaluate the impact of organophosphates on semen parameters with six of them eligible for meta-analysis. A significant reduction was detected for the following: ejaculate volume (WMD −0,47ml, 95%CI −0,69 to −0,25; p < 0,0001), sperm count (WMD-40,03, 95%CI −66,81 to −13,25;p = 0,003), concentration (WMD-13,69 x106/mL, 95%CI −23, 27 to-4,12;p = 0,005) and motility (WMD −5,70%, 95%CI −12,89 to 1,50;p = 0,12). Despite the increase in sperm abnormality, it has been shown that pyrethroids are unrelated to reduced sperm quality. However, the negative association of organophosphates with spermatogenesis is noteworthy
    corecore